Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APTneo: Atezolizumab + Pertuzumab + Trastuzumab with chemotherapy as neoadjuvant treatment of HER2-positive high-risk and locally advanced breast cancer
2024-518026-32-00Phase 3Authorised
- Sponsor
- Michelangelo Foundation
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3 trial of atezolizumab, pertuzumab, trastuzumab and trastuzumab emtansine in breast cancer, sponsored by Michelangelo Foundation. Primary endpoint: Event Free Survival (EFS). Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-518026-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518026-32-00.